Lakefront Biotherapeutics (LKFT) Common Equity (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Common Equity of $3.8 billion for Q1 2026, up 31.77% year-over-year from $2.9 billion in Q1 2025, and up 1.12% quarter-over-quarter from $3.8 billion in Q4 2025.
Lakefront Biotherapeutics (LKFT) Common Equity (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Common Equity for 13 consecutive years, with $3.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 31.77% year-over-year to $3.8 billion; the TTM figure through Mar 2026 stood at $3.8 billion (up 31.77% YoY), while the FY2025 annual figure was $3.8 billion, up 21.68% from the prior year.
- Common Equity rose to $3.8 billion in Q1 2026 per LKFT's latest filing, from $3.8 billion in the prior quarter.
- Across five years, Common Equity topped out at $3.8 billion in Q1 2026 and bottomed at $2.6 billion in Q4 2022.
- Historically, Common Equity has averaged $3.1 billion across 5 years, with a median of $3.0 billion in 2025.
- Annual changes were most pronounced in 2022 — Common Equity dropped 14.77% — and 2026, when it jumped 31.77%.
- Lakefront Biotherapeutics' Common Equity stood at $2.6 billion in 2022, then advanced by 16.71% to $3.0 billion in 2023, then grew by 2.92% to $3.1 billion in 2024, then rose by 21.68% to $3.8 billion in 2025, then climbed by 1.12% to $3.8 billion in 2026.
- Business Quant data shows LKFT's Common Equity at $3.8 billion in Q1 2026, $3.8 billion in Q4 2025, and $2.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 3.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.81 Bn |
| Dec 31, 2025 | 3.77 Bn |
| Sep 30, 2025 | 2.86 Bn |
| Jun 30, 2025 | 2.99 Bn |
| Mar 31, 2025 | 2.89 Bn |
| Dec 31, 2024 | 3.10 Bn |
| Sep 30, 2024 | 3.14 Bn |
| Mar 31, 2024 | 3.15 Bn |
| Dec 31, 2023 | 3.01 Bn |
| Sep 30, 2023 | 2.85 Bn |
| Mar 31, 2023 | 2.75 Bn |
| Dec 31, 2022 | 2.58 Bn |
| Mar 31, 2022 | 2.97 Bn |
| Dec 31, 2021 | 3.02 Bn |
| Jun 30, 2021 | 3.21 Bn |
| Dec 31, 2020 | 3.18 Bn |
| Jun 30, 2020 | 3.05 Bn |
| Mar 31, 2020 | 3.14 Bn |
| Dec 31, 2019 | 3.18 Bn |
| Sep 30, 2019 | 2.82 Bn |